FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Group |
| Id | Group-279346.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
FHIR
FHIRsmith{
"resourceType": "Group",
"id": "279346",
"meta": {
"versionId": "11",
"lastUpdated": "2025-03-15T21:00:24.258Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"
]
},
"language": "en",
"text": {
"status": "empty",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail": {
"name": "Brian S. Alper"
}
},
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
"valueMarkdown": "ConceptualCohortDefinition: T2DM-specific criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279346. Revised 2024-11-16. Available at: https://fevir.net/resources/Group/279346. Computable resource at: https://fevir.net/resources/Group/279346#json."
},
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Group/279346",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "279346",
"assigner": {
"display": "Computable Publishing LLC"
}
}
],
"title": "ConceptualCohortDefinition: T2DM-specific criteria",
"status": "active",
"publisher": "Computable Publishing LLC",
"contact": [
{
"telecom": [
{
"system": "email",
"value": "support@computablepublishing.com"
}
]
}
],
"description": "i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria\nii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine\niii. are between 20 and 70 years old at the time of informed consent\niv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"membership": "conceptual",
"combinationMethod": "all-of",
"characteristic": [
{
"code": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "64572001",
"display": "Disease (disorder)"
}
]
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "44054006",
"display": "Diabetes mellitus type 2 (disorder)"
}
]
},
"exclude": false,
"description": "Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria",
"method": [
{
"text": "based on the World Health Organization (WHO) diagnostic criteria"
}
]
},
{
"code": {
"text": "Medication exposure"
},
"valueCodeableConcept": {
"text": "Daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs)\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine"
},
"exclude": false,
"description": "Have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year\n..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII\n..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine",
"durationDuration": {
"value": 1,
"comparator": ">=",
"unit": "years",
"system": "http://unitsofmeasure.org",
"code": "a"
}
},
{
"code": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "397669002",
"display": "Age"
}
]
},
"valueRange": {
"low": {
"value": 20,
"unit": "years",
"system": "http://unitsofmeasure.org",
"code": "a"
},
"high": {
"value": 70,
"unit": "years",
"system": "http://unitsofmeasure.org",
"code": "a"
}
},
"exclude": false,
"description": "Are between 20 and 70 years old at the time of informed consent",
"timing": [
{
"contextCode": {
"coding": [
{
"system": "http://snomed.info/sct",
"code": "182771004",
"display": "Informed consent for procedure"
}
]
},
"offsetDuration": {
"value": 0
}
}
]
},
{
"code": {
"coding": [
{
"system": "http://loinc.org",
"code": "39156-5",
"display": "Body mass index (BMI) [Ratio]"
}
]
},
"valueRange": {
"low": {
"value": 18.5,
"unit": "kilogram per square meter (kg/m2)",
"system": "http://unitsofmeasure.org",
"code": "kg/m2"
},
"high": {
"value": 35,
"unit": "kilogram per square meter (kg/m2)",
"system": "http://unitsofmeasure.org",
"code": "kg/m2"
}
},
"exclude": false,
"description": "Have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening",
"timing": [
{
"contextCode": {
"text": "screening"
},
"offsetDuration": {
"value": 0
}
}
]
}
]
}